EGFR and non-small cell lung carcinoma: A meta‐analysis of five clinical trials that included 3,025 patients with advanced NSCLC who were treated with a PD‐L1 inhibitor found that, among patients with EGFR mutations, the overall survival (OS) was not improved compared to those treated with docetaxel.15